

MEDICAL POLICY

Medical Policy Title	Serum Antibodies for the Diagnosis of Inflammatory Bowel Disease
Policy Number	2.02.19
Current Effective Date	November 20, 2025
Next Review Date	November 2026

Our medical policies are based on the assessment of evidence based, peer-reviewed literature, and professional guidelines. Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract. (Link to [Product Disclaimer](#))

POLICY STATEMENT(S)

- I. Serologic testing of biomarkers including, but not limited to anti-neutrophil cytoplasmic antibodies (ANCA) or anti-Saccharomyces cerevisiae (ASCA); antibodies of outer membrane porin C of the bacteria Escherichia coli (anti-OmpC); Pseudomonas fluorescens-associated sequence I2 (anti-I2); flagellin CBir1 (anti-cBir1); antichitobioside antibodies (ACCA IgA); antilaminaribioside antibodies (ALCA IgG); and antimannobioside antibodies (AMCA IgG) (e.g.; Prometheus IBD sgi Diagnostic testing), is considered **not medically necessary** for **ALL** indications including, but not limited to:
 - A. To diagnose and monitor patients with inflammatory bowel disease (IBD);
 - B. To distinguish ulcerative colitis (UC) from Crohn's disease (CD).

RELATED POLICIES

Not Applicable

POLICY GUIDELINE(S)

Laboratories performing clinical tests must be certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA).

DESCRIPTION

Inflammatory bowel disease (IBD) is a chronic disease of the gastrointestinal tract that consists of two related diseases, ulcerative colitis (UC) and Crohn's disease (CD). Although UC and CD are generally considered distinctive forms of IBD, their clinical presentations commonly overlap. Furthermore, for approximately 10-15% of patients with IBD, the distinction between UC and CD cannot be made with certainty. These patients are given a diagnosis of indeterminate colitis (IC). A correct diagnosis of IBD, especially the differentiation between CD and UC is highly important in determining treatment and prognosis. The diagnostic work-up of patients with IBD is relatively complicated, and endoscopic exam and biopsy are currently crucial components of the diagnosis. Less invasive, accurate diagnostic tools to distinguish between UC, CD, and cases of indeterminate colitis are needed.

Medical Policy: Serum Antibodies for the Diagnosis of Inflammatory Bowel Disease

Policy Number: 2.02.19

Page: 2 of 7

It has been proposed that serological markers for IBD can be utilized, both to differentiate UC from CD, and to define patient subgroups (e.g., location of the disease, such as proximal versus distal bowel involvement). Other potential uses include determination of disease severity, prediction of response to anti-tumor necrosis factor (TNF) therapy, and identification of the susceptibility to IBD among family members of an affected individual. Anti-neutrophil cytoplasmic antibodies (ANCA) and anti-Saccharomyces cerevisiae antibodies (ASCA) have been the most extensively studied serological markers for use in the diagnosis of IBD. ANCA are a group of antibodies, which are specific for granulocyte antigens. Anti-neutrophil cytoplasmic antibodies with perinuclear staining (pANCA) have been most commonly described in IBD and have been linked with UC. Other antibodies that have recently been associated with CD include anti-OmpC, anti-cBir1, Anti-I2, ACCA, ALCA, and AMCA. Increased amounts and levels of an antibody's response have been suggested to predict a more complicated course of disease. Large prospective studies are needed, to validate these findings.

Recent data suggest that the presence of serological biomarkers might represent a genetic susceptibility, because patients who have positive antibodies may carry mutations in the NOD2/CARD15 gene or in toll-like receptor genes. However, future studies of larger cohorts with well-defined clinical characteristics and patient populations are needed, to determine the validity of this relationship.

The PROMETHEUS IBD sgi Diagnostic aims to help identify IBD and differentiates between UC and CD. It may also assess a patient's risk for more aggressive disease. The test includes the proprietary and patented serologic markers anti-CElir1, Anti-OmpC and DNase-sensitive pANCA process as well as, the markers ASCA IgA (ACCA) and IgG (ALCA and AMCA). The sgi Diagnostic test also includes the ATG16L, ECM1, mkX2-3, and STAT3 genetics and inflammation markers such as VEGF, ICAM-1, VACAM-1, CRP, and SAA. The Smart Diagnostic Algorithm technology produces an IBD score; results are reported as consistent with IBD (consistent with ulcerative colitis, consistent with CD, or inconclusive for ulcerative colitis vs. CD) or not consistent with IBD. The test is intended for use in patients with clinical suspicion of IBD.

SUPPORTIVE LITERATURE

A published study compared the predictive values of the Prometheus Inflammatory Bowel Disease (IBD) Serology 7 (IBD7) panel (Prometheus Laboratories, San Diego, CA) with the predictive values of routine blood tests in a population of children referred for initial evaluation of suspected IBD (Benor 2010). Medical records of pediatric patients referred for evaluation of IBD for whom IBD7 testing was performed at Prometheus Laboratories between January 2006 and November 2008 were reviewed. Patients underwent diagnosis by pediatric gastroenterologists on the basis of clinical, radiologic, endoscopic, and pathologic evaluations. A total of 394 records were identified and 90 records were excluded on the basis of age of >21 years, previous diagnosis of IBD, or unclear diagnosis. The prevalence of IBD in this cohort was 38%. The sensitivity, specificity, positive predictive value, negative predictive value, and kappa value for the serological panel were 67%, 76%, 63%, 79%, and 42%, respectively, compared with values for a combination of three (3) abnormal routine laboratory test results of 72%, 94%, 85%, 79%, and 47%. The anti-flagellin antibody assay, the newest assay added to the panel, had sensitivity of 50% and specificity of 53%. Repeat serological testing failed to produce consistent results for four (4) of 10 patients. The authors

Medical Policy: Serum Antibodies for the Diagnosis of Inflammatory Bowel Disease

Policy Number: 2.02.19

Page: 3 of 7

concluded this study showed, the IBD7 panel has lower predictive values than routine laboratory tests in pediatric screening for IBD.

The use of serological markers for patients with IBD has not been shown to improve health outcomes by reducing the need for other tests nor has it been proven to increase the accuracy of diagnosis for these patients. Large-scale prospective studies are required, to ascertain the predictive value and cost-effectiveness of the use of these serology markers in the screening and monitoring of IBD patients.

PROFESSIONAL GUIDELINE(S)

The American College of Gastroenterology (ACG) published clinical guidelines for the management of Crohn's disease in adults (Lichtenstein 2025). They do not support serologic testing and state the following:

- "Routine use of serologic markers of IBD to establish the diagnosis of Crohn's disease is not indicated."
- "Because of the heterogeneous nature of IBD there has been extensive research directed toward finding immunologic markers that would assist in disease diagnosis. These studies have focused on antibodies to microbial antigens and autoantibodies. Antiglycan antibodies are more prevalent in CD than in UC but have a low sensitivity, making their use in diagnosis less helpful. Tests have been developed that use a combination of serologic, genetic, and inflammatory markers to try to improve diagnostic efficacy; however, this combination of markers has not improved serology measurements usefulness as a screening tool."

ACG published clinical guidelines for the management of ulcerative colitis in adults (Rubin 2025). They do not support serologic testing and state the following:

- "We recommend against serologic antibody testing to establish or rule out a diagnosis of UC (strong recommendation, very low quality of evidence)"
- "We recommend against serologic antibody testing to determine the prognosis of UC (strong recommendation, very low quality of evidence)."
- "Serologic markers such as perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) may be found in up to 70% of patients with UC, and combination of negative anti-Saccharomyces cerevisiae (ASCA) antibodies with elevated pANCA levels have been proposed to facilitate establishing a diagnosis of UC. However, the pooled sensitivity of antibody testing for diagnosis of UC is low, and such markers are not used for establishing or ruling out a diagnosis of UC. While pANCA positivity has also been associated with treatment refractory UC, the evidence supporting this is limited and there is currently no role for such testing to determine the likelihood of disease evolution and prognosis."

REGULATORY STATUS

Medical Policy: Serum Antibodies for the Diagnosis of Inflammatory Bowel Disease

Policy Number: 2.02.19

Page: 4 of 7

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service. Laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA).

Laboratories that offer laboratory-developed tests must be licensed by CLIA for high-complexity testing. More information is available at: [Clinical Laboratory Improvement Amendments \(CLIA\) | FDA](#) [accessed 2025 Sep 23]

CODE(S)

- Codes may not be covered under all circumstances.
- Code list may not be all inclusive (AMA and CMS code updates may occur more frequently than policy updates).
- (E/I)=Experimental/Investigational
- (NMN)=Not medically necessary/appropriate

CPT Codes

Code	Description
There are no specific CPT codes.	Codes 81479, 82397, 83516 83520, 86140, 88346 or 88350 may be used for billing PROMETHEUS IBD sgi Diagnostic; however, these codes are not specific to PROMETHEUS IBD.

Copyright © 2025 American Medical Association, Chicago, IL

HCPCS Codes

Code	Description
Not Applicable	

ICD10 Codes

Code	Description
K50.00- K50.919	Crohn's disease [regional enteritis] (code range)
K51.00- K51.919	Ulcerative colitis (code range)

REFERENCES

Annes V, et al. Familial expression of anti-Saccheromyces cerevisiae mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study. Am J Gastroenterol. 2001;96(8):2407-12.

Medical Policy: Serum Antibodies for the Diagnosis of Inflammatory Bowel Disease

Policy Number: 2.02.19

Page: 5 of 7

- Benor S, et al. Shortcomings of the inflammatory bowel disease Serology 7 panel. *Pediatrics*. 2010 Jun;125(6):1230-6.
- Bernstein CN, et al. Development of an assay for antibodies to *Saccharomyces cerevisiae*: easy, cheap, and specific for Crohn's disease. *Can J Gastroenterol*. 2001 Aug;15(8):499-504.
- Bonneau J, et al. Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF-Ab) in the prediction of IBD patient outcomes. *Autoimmun Rev*. 2015 Mar;14(3):231-45.
- Desir B, et al. Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. *Clin Gastroenterol Hepatol*. 2004 Feb;2(2):139-146.
- Dotan I. New serologic markers for inflammatory bowel disease diagnosis. *Dig Dis*. 2010;28(3):418-23.
- Fengming Y, et al. Biomarkers of inflammatory bowel disease. *Dis Markers*. 2014:710915.
- Forcione DG, et al. Anti-saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. *Gut*. 2004 Aug;53(8):1117-22.
- Iskandar HN, et al. Biomarkers in inflammatory bowel disease: current practices and recent advances. *Transl Res*. 2012 Apr;153(4):313-25.
- Kaul A, et al. Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: a systematic review and meta-analysis. *Inflamm Bowel Dis*. 2012 Oct;28(10):1872-84.
- Kevans D, et al. Serological markers associated with disease behavior and response to anti-tumor necrosis factor therapy in ulcerative colitis. *J Gastroenterol Hepatol*. 2015 Jan;30(1):64-70.
- Kim BG, et al. Diagnostic role of anti-Saccharomyces mannan antibodies combined with antineutrophil cytoplasmic antibodies in patients with inflammatory bowel disease. *Dis Colon Rectum*. 2002 Aug;45(8):1062-9.
- Lichtenstein GR, et al. Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior. *Inflamm Bowel Dis*. 2011 Dec;17(12):2488-96.
- Lichtenstein GR, et al. ACG Clinical Guideline: management of Crohn's disease in adults. *Am J Gastroenterol*. 2025 Jun 3;120(6):1225-1264.
- Mitsuyama K, et al. Antibody markers in the diagnosis of inflammatory bowel disease. *World J Gastroenterol*. 2016 Jan 21;22(3):1304-10.
- Papp M, et al. Serological studies in inflammatory bowel disease: how important are they? *Curr Opin Gastroenterol*. 2014 Jul;30(4):359-64.
- Peng C., et al. Serum biomarkers for inflammatory bowel disease. *Front Med*. 2020 Apr; 7:123.
- Rubin DT, et al. ACG Clinical Guideline Update: ulcerative colitis in adults. *Am J Gastroenterol*. 2025 Jun 3;120(6):1187-1224.
- Ryan JD, et al. Predicting complicated Crohn's disease and surgery: phenotypes, genetics, serology, and psychological characteristics of a population-based cohort. *Aliment Pharmacol Ther*. 2013 Aug;38(3):274-83.

Medical Policy: Serum Antibodies for the Diagnosis of Inflammatory Bowel Disease

Policy Number: 2.02.19

Page: 6 of 7

Schoepfer AM, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. *Inflamm Bowel Dis.* 2008; 14(1):32-9.

Sipeki N, et al. Prevalence, significance, and predictive value of antiphospholipid antibodies in Crohn's disease. *World J Gastroenterol.* 2015 Jun 14;21(22):6952-64.

Smids C, et al. The value of serum antibodies in differentiating inflammatory bowel disease, predicting disease activity and disease course in the newly diagnosed patient. *Scand J Gastroenterol.* 2017 Oct;52(10):1104-1112.

Torres J, et al. Predicting outcomes to optimize disease management in inflammatory bowel diseases. *J Crohns Colitis.* 2016 Dec;10(12):1385-1394.

Vermeire S, et al. Classification of inflammatory bowel disease: the old and the new. *Curr Opin Gastroenterol.* 2012 Jul;29(4):321-6.

Vermeire S, et al. (Auto)Antibodies in Inflammatory Bowel Diseases. *Gastroenterol Clin N Am.* 2008; 37:429-38.

Vermeire S, et al. Comparative study of ASCA (Anti-saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. *Gastroenterol.* 2001 Mar;120 (4):827-33.

Zholudev A, et al. Serologic testing with ANCA, ASCA and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. *Am J Gastroenterol.* 2004 Nov;99(11):2235-41.

SEARCH TERMS

Anti-neutrophil cytoplasmic antibodies, ANCA, Anti-Saccharomyces cerevisiae, ASCA, Crohn's disease, Inflammatory bowel disease, Prometheus Labs, Serological markers, Ulcerative colitis.

CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS)

Based on our review, Serological Diagnosis of Inflammatory Bowel Disease or Prometheus IBD is not addressed in National or Regional Medicare coverage determinations or policies.

PRODUCT DISCLAIMER

- Services are contract dependent; if a product does not cover a service, medical policy criteria do not apply.
- If a commercial product (including an Essential Plan or Child Health Plus product) covers a specific service, medical policy criteria apply to the benefit.
- If a Medicaid product covers a specific service, and there are no New York State Medicaid guidelines (eMedNY) criteria, medical policy criteria apply to the benefit.
- If a Medicare product (including Medicare HMO-Dual Special Needs Program (DSNP) product) covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.

Medical Policy: Serum Antibodies for the Diagnosis of Inflammatory Bowel Disease

Policy Number: 2.02.19

Page: 7 of 7

- If a Medicare HMO-Dual Special Needs Program (DSNP) product DOES NOT cover a specific service, please refer to the Medicaid Product coverage line.

POLICY HISTORY/REVISION	
Committee Approval Dates	
05/21/03, 04/15/04, 02/17/05, (Deleted 10/20/05-01/21/10), 01/21/10, 11/17/11, 12/20/12, 12/19/13, 11/20/14, 11/19/15, 11/17/16, 11/16/17, 12/20/18, 12/19/19, 12/17/20, 12/16/21, 11/17/22, 11/16/23, 11/21/24, 11/20/25	
Date	Summary of Changes
11/20/25	<ul style="list-style-type: none">• Annual review, policy intent unchanged.
01/01/25	<ul style="list-style-type: none">• Summary of changes tracking implemented.
05/21/03	<ul style="list-style-type: none">• Original effective date